8- -cGMP

PEGULATORYAGENCIES - PHARMACEUTICALSANDCOSTffiTICS] (Vol21) cGMP. See Cydic-guanosine monophosphate. 

The ANP leceptoi exists in two forms, ANP and ANPg, both of which have been cloned. These membrane-bound guanylate cyclases have a single transmembrane domain, an intracellular protein kinase-like domain, and a catalytic cyclase domain, activation of which results in the accumulation of cychc guanosine monophosphate (cGMP). A third receptor subtype (ANP ) has been identified that does not have intrinsic guanylate cyclase activity and may play a role in the clearance of ANP. 

Other offices within ODER may become involved in the review process via consults. Eor example, the Office of Epidemiology and Biostatistics analyzes statistical data, the Office of Research Resources provides bioavailabiHty reviews, and the Office of Compliance determines from the results of inspections whether the firms meet EDA s Current Good Manufacturing Practice (cGMP) regulations. Advisory committees composed of independent experts are often asked to meet and further analyze the data. Often they also advise as to what additional data and information may be needed. After PDA s review is completed, PDA issues either a Summary Basis of Approval (SBA) for the dmg or a recommendation against approval. If approved, PDA releases the SBA and a summary of the safety and effectiveness data to the general pubHc. 

In the preparation of classical killed or toxoid vaccines, simple process technology was used. With the advance of new vaccines, far more sophisticated process technologies are needed. The desire to reduce side effects of vaccination requires processes which will yield antigens of extreme purity. The new regulation in cGMP requires consistent production procedures, and global competition also demands that the most efficient process technology be appHed. 

Vasodilators dilate or relax the smooth muscles of the vasculatures directly or iadirecfly by releasiag endogenous vasodepressors or antagoni2iag the endogenous vasopressors or vasopressor systems (200,243,244). Vasodilators may iaterfere with the entry, iatraceUular release, and utili2ation of calcium, the activation of the proteia kinase C system, cGMP formation, and EDRF turnover. 

FIGURE 11.14 Structures of the cyclic nucleotides cAMP aud cGMP. 

The design of the system must take into account possible variation of critical control parameters that could affect performance. The maximum performance of the process should be defined by a reasonable safety margin. In order to comply with cGMP guidelines, established validation protocols, and parameters should allow the process to achieve reproducible purity and yield under stressed conditions. This implies that the industrial SMB system must be stressed to simulate worst-case conditions for process validation. 

From the position of the FDA, acceptance of SMB as a viable tool for cGMP manufacturing of enantiopure drug substances, there shall be no compromise, it must be properly engineered, and follow established guidelines. 

---